Risultati per: Nuovi possibili trattamenti per il morbo di Alzheimer

Il 50% di probabilità in più anche per altre malattie neurodegenerative

Il 50% di probabilità in più anche per altre malattie neurodegenerative

Uno biologico e sperimentale dal 15 aprile,l’altro psicoterapico

Ricerca Centro medicina sonno Molinette di Torino e Università

This exploratory case-control study assesses the association of APOE missense variants with risk of Alzheimer disease among individuals of African ancestry with the APOE ε3/ε4 genotype.

In Rsa S. Raffaele musicoterapia per stimolazione cognitiva

A base di pseudoefedrina, ancora nessun provvedimento.

A treatment that may moderately slow mild cognitive decline and reduce amyloid-β plaques in patients with early Alzheimer disease gained accelerated approval from the US Food and Drug Administration (FDA). Lecanemab-irmb, marketed as Leqembi by Eisai and Biogen, is indicated for patients with mild cognitive impairment or mild dementia due to Alzheimer disease.

Stroke, Volume 54, Issue Suppl_1, Page AWP238-AWP238, February 1, 2023. Introduction:The aquaporin-4 (AQP4)-dependent glymphatic system mediates β-amyloid (Aβ) clearance. Using TgF344-AD rats that recapitulate clinical hallmarks of Alzheimer’s disease (AD), we examined longitudinal alterations of the AQP4-glymphatic system during the progression of Aβ deposition and cognitive decline.Methods:Male and female TgF344-AD rats (n=34, 18 male and 16 female) and wildtype (WT) littermates (n=30, 15 male and 15 female) rats at the ages of 6, 10, and 20 months (M) were subjected to an array of cognitive function tests. Aβ and AQP4 were measured using immunohistochemistry and the glymphatic system was measured using magnetic resonance imaging (MRI).Results:Compared to age-matched WT rats, TgF344-AD rats showed progressive cognitive deficits measured by odor recognition, social interaction, and Morris water maze tests starting from 10M and declining through 20M with worse cognitive deficit in female rats. Compared to WT rats, a significant reduction of para-arteriole AQP4 started at 6M (21±7%) and progressed to microvessels (55±12%) in the hippocampus and cortex through 20M, while Aβ deposition nearby reduced AQP4 started at 6M (6±2%) and widely expanded during 10M (31±9%) to 20M (42±7%). Aβ deposition was significantly correlated to cognitive deficit with R2of 0.95. During 10M to 20M extravascular albumin deposition was detected. MRI analysis revealed that TgF344-AD rats exhibited significantly decreased glymphatic clearance rate of Gd-DTPA starting at 10M, which was further aggravated at 20M.Conclusion:Our data demonstrate that female TgF344-AD rats have worse cognitive deficits and increased loss of AQP4 prior to cognitive deficits, Aβ deposition, and dysfunction of the glymphatic system. These data support that the AQP4-dependent glymphatic system plays an important role in mediating the progression of AD pathologies in the rat.

In an 18-month randomized trial, the drug had a modest effect, of questionable clinical relevance.

Indotti da proteine casearie e antiossidanti della nera bevanda

Nelle donne è associata a migliore memoria e capacità cognitive

Two early clinical studies suggest that sensory stimulation with light and sound should be studied further for its potential to slow neurodegeneration and improve behavioral function in mild Alzheimer disease, according to a report in PLOS ONE.

Studio su Brain vede coinvolti anche ricercatori di Brescia

Ha mostrato di rallentare la malattia, costerà 26.500 dollari all’anno a persona